Highlights

  • There is no single ASX announcement dated to 8-10 August that explains the move.
  • FY26 group Revenue came in at US$23.7 million, up 26% on the prior year - the fourth consecutive year of growth above 25%.
  • Nova Eye has an investor webinar scheduled for August 2026, which should give management a chance to expand on FY27 guidance and the path to sustained profitability.
  • The flip side is equally real. Nova Eye remains loss-making on a full-year basis, cash reserves are thin relative to the scale of the US sales push, and consensus Earnings estimates have been trimmed even...

Nova Eye Medical shares were among the ASX's stronger movers this week, adding a further 6.45% on a TradingView top-gainers screener taken around 8-10 August 2026. It's the latest leg of a rally that has taken the small-cap glaucoma device maker from around 13 cents in early August to roughly 16 cents by the 10th, a run of daily gains that follows a full-year result showing the company's fastest sustained sales growth streak yet and its first taste of positive earnings. For a stock that has spent years burning cash while it built out its US sales operation, a run of green candles on modest turnover is the kind of thing shareholders notice. Nothing here is a single, dramatic catalyst - it looks more like a market slowly re-rating a company that has just posted the numbers it long promised. That distinction matters for anyone trying to work out what comes next.

Recent Developments

There is no single ASX announcement dated to 8-10 August that explains the move. Instead, the rise sits on top of a genuine, verifiable fundamental trigger from a fortnight earlier: on 29 July 2026, Nova Eye lodged its Appendix 4C quarterly cashflow report for the June quarter alongside full-year FY26 results, headlined "Record April Sales Drive FY26 Guidance Upgrade" earlier in May and then confirmed with the year-end numbers. The stock has been grinding higher in the sessions since, climbing from about 13 cents on 3 August to 16 cents by 7 August, with daily moves as large as 7.7% along the way, before the further gain captured on the 8-10 August screener.

Small-cap, thinly traded stocks like EYE can move sharply on relatively low volumes, and coverage of an earlier 8.7% jump in late July noted explicitly that "the supplied market data did not identify a single announcement as the sole driver of the session's rise." The same appears true here: this looks like sustained buying interest following a strong result, rather than a fresh, discrete piece of news on the day.

Why It Matters

Nova Eye has been a story stock for a while - a genuine clinical product, a growing US footprint, but a Balance Sheet that kept needing topping up. The FY26 result changes the framing slightly. Revenue excluding China rose 29% to US$22.7 million, ahead of the company's own May guidance midpoint, and the second half delivered positive EBITDA of US$0.14 million versus a loss in the prior corresponding half. For a company that has never posted a profitable period, that inflection point is the sort of thing that gets small-cap investors interested again, even if the headline dollar amount is modest.

The case for optimism is straightforward: four straight years of 25%-plus growth, an EBITDA inflection in the second half, and management penetration estimates of only around 4% of the roughly 30,000-35,000 monthly eligible glaucoma procedures in the US - implying a long runway if adoption continues. Stable US Medicare reimbursement rates for 2027 remove one source of near-term policy risk, and analyst consensus (albeit from a thin field of two contributors) carries a price target well above the current share price, reflecting the growth-versus-valuation gap that often exists in early-profitability MedTech names.

The Assets described above remain central to the company's valuation and strategic case.

Investment decisions remain tied to the milestones, funding needs and risks outlined above.

Company Overview

Nova Eye Medical designs, manufactures and sells ophthalmic surgical devices focused on glaucoma treatment. Its flagship product is iTrack, an illuminated microcatheter used in canaloplasty - a minimally invasive glaucoma surgery (MIGS) technique that widens the eye's natural drainage channel to lower intraocular pressure. The original iTrack device has been used in more than 150,000 procedures since 2008; the newer iTrack Advance adds an ergonomic handpiece and proprietary viscoelastic technology aimed at improving outflow. The company also sells Molteno3, a glaucoma drainage device for more advanced or complex cases.

The Business traces back to 1994 and was known as Ellex Medical Lasers before rebranding as Nova Eye Medical in 2020, after divesting its lasers and ultrasound division to France's Lumibird Group. Manufacturing is split between Fremont, California, and Dunedin, New Zealand, with the commercial engine increasingly centred on the United States, which now accounts for the bulk of group revenue.

Financial Snapshot

FY26 group revenue came in at US$23.7 million, up 26% on the prior year - the fourth consecutive year of growth above 25%. The United States delivered US$18.6 million, up 30%, with the fourth quarter alone growing 33% to US$5.5 million; management flagged July trading continuing at a similar 30% pace. Germany added US$2.0 million (up 5%) and the rest of the world US$2.1 million (up 47%). Gross Margin improved to 73% in the second half, from 70% a year earlier.

On profitability, the full-year EBITDA loss narrowed to US$1.3 million from US$3.5 million in FY25, with the second half alone turning EBITDA-positive at US$0.14 million. For FY27, Nova Eye is guiding to ex-China revenue of US$26-31 million - roughly 20% growth at the midpoint - while targeting a full-year positive EBITDA result. Cash on hand sits at around AUD 1.0 million, backed by AUD 2.7 million of unused Debt facilities, for total Liquidity of about AUD 3.7 million; quarterly operating cash outflow has narrowed to AUD 0.2 million. As at 10 August 2026, the stock traded around AUD 0.16, valuing the company at roughly AUD 42-43 million.

Cash Flow remains central to funding capacity and the company's ability to execute its next milestones.

Capital requirements remain central to the company's development and operating plans.

Market Capitalisation remains a useful reference point for how the market is valuing the story described above.

What to Watch

Nova Eye has an investor webinar scheduled for August 2026, which should give management a chance to expand on FY27 guidance and the path to sustained profitability. The next hard data point will be the September-quarter Appendix 4C, due around late October, which will show whether the improving cash-burn trend from Q4 FY26 has continued. Shareholders will be watching US sales growth rates and gross margin trends closely, since both are central to whether the FY27 EBITDA-positive target is realistic.

Risks

The flip side is equally real. Nova Eye remains loss-making on a full-year basis, cash reserves are thin relative to the scale of the US sales push, and consensus earnings estimates have been trimmed even as the growth story has held up - a sign forecasting this business remains difficult. Liquidity in the shares is limited, which cuts both ways: it can amplify rallies like this one, but it can just as easily amplify reversals. Execution risk around US reimbursement, surgeon adoption curves and competitive MIGS devices also remains part of the equation.

What Could Keep Nova Eye's Earnings Recovery Building

This is a rally built on fundamentals rather than a single headline - a small-cap medtech name re-rating after finally showing the market a profitable half, not a stock jumping on a discrete announcement. That makes it arguably more durable than a one-day news spike, but it also means the next test is whether Nova Eye can convert quarter-on-quarter sales growth into a full financial year of positive earnings, as guided.